Format

Send to

Choose Destination
Int J Mol Sci. 2011;12(6):4027-52. doi: 10.3390/ijms12064027. Epub 2011 Jun 15.

Systematic approaches towards the development of host-directed antiviral therapeutics.

Author information

1
Department of Chemistry, Emory University, Atlanta, GA 30322, USA; E-Mails: aprussi@emory.edu (A.P.); jsnyder@emory.edu (J.P.S.).

Abstract

Since the onset of antiviral therapy, viral resistance has compromised the clinical value of small-molecule drugs targeting pathogen components. As intracellular parasites, viruses complete their life cycle by hijacking a multitude of host-factors. Aiming at the latter rather than the pathogen directly, host-directed antiviral therapy has emerged as a concept to counteract evolution of viral resistance and develop broad-spectrum drug classes. This approach is propelled by bioinformatics analysis of genome-wide screens that greatly enhance insights into the complex network of host-pathogen interactions and generate a shortlist of potential gene targets from a multitude of candidates, thus setting the stage for a new era of rational identification of drug targets for host-directed antiviral therapies. With particular emphasis on human immunodeficiency virus and influenza virus, two major human pathogens, we review screens employed to elucidate host-pathogen interactions and discuss the state of database ontology approaches applicable to defining a therapeutic endpoint. The value of this strategy for drug discovery is evaluated, and perspectives for bioinformatics-driven hit identification are outlined.

KEYWORDS:

HIV; Influenza virus; RNAi; antiviral; bioinformatics; genome-wide screening; pathway analysis; siRNA; target identification

PMID:
21747723
PMCID:
PMC3131607
DOI:
10.3390/ijms12064027
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center